Avant Immunotherapeutics RSS Feed | Nachrichten | finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifFinanzen.nethttp://www.finanzen.netCORRECTING and REPLACING AVANT Reports Second Quarter and Six Month Financial Resultshttp://www.finanzen.net/nachricht/CORRECTING_and_REPLACING_AVANT_Reports_Second_Quarter_and_Six_Month_Financial_Results_765696Please replace the release with the following corrected version due to multiple revisions. AVANT REPORTS SECOND QUARTER AND SIX MONTH FINANCIAL RESULTS Conference Call Wednesday, August 6 at 9:00 a.m. Eastern Time AVANT Immunotherapeutics, ...http://www.finanzen.net/nachricht/CORRECTING_and_REPLACING_AVANT_Reports_Second_Quarter_and_Six_Month_Financial_Results_765696AVANT Reports Second Quarter and Six Month Financial Resultshttp://www.finanzen.net/nachricht/AVANT_Reports_Second_Quarter_and_Six_Month_Financial_Results_765346AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today reported financial results for the second quarter and six-month period ended June 30, 2008. AVANT reported a net loss of $10.3 million, or $0.67 per share, for the second quarter ...http://www.finanzen.net/nachricht/AVANT_Reports_Second_Quarter_and_Six_Month_Financial_Results_765346AVANT to Report Second Quarter 2008 Financial Results on August 6, 2008http://www.finanzen.net/nachricht/AVANT_to_Report_Second_Quarter_2008_Financial_Results_on_August_6_2008_763571AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its second quarter 2008 financial results before U.S. financial markets open on August 6, 2008. AVANT executives will host a conference call and live audio webcast at ...http://www.finanzen.net/nachricht/AVANT_to_Report_Second_Quarter_2008_Financial_Results_on_August_6_2008_763571AVANT Announces Vaccine Adjuvant Licenses with 3Mhttp://www.finanzen.net/nachricht/AVANT_Announces_Vaccine_Adjuvant_Licenses_with_3M_739622Celldex Therapeutics, Inc. (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) today announced multi-year clinical research collaborations with the 3M to access their proprietary Immune Response Modifier Resiquimod™ ...http://www.finanzen.net/nachricht/AVANT_Announces_Vaccine_Adjuvant_Licenses_with_3M_739622AVANT CEO to Present at the Needham & Company Biotechnology & Medical Technology Conferencehttp://www.finanzen.net/nachricht/AVANT_CEO_to_Present_at_the_Needham__Company_Biotechnology__Medical_Technology_Conference_736543AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the Seventh Annual Needham & Company, LLC Biotechnology ...http://www.finanzen.net/nachricht/AVANT_CEO_to_Present_at_the_Needham__Company_Biotechnology__Medical_Technology_Conference_736543NIH Initiates Phase 1 Safety Study of AVANT's Oral Combined Enterotoxigenic E. coli-Cholera Vaccinehttp://www.finanzen.net/nachricht/NIH_Initiates_Phase_1_Safety_Study_of_AVANT_s_Oral_Combined_Enterotoxigenic_E_coli_Cholera_Vaccine_736361AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes ...http://www.finanzen.net/nachricht/NIH_Initiates_Phase_1_Safety_Study_of_AVANT_s_Oral_Combined_Enterotoxigenic_E_coli_Cholera_Vaccine_736361AVANT Reports First Quarter 2008 Financial Resultshttp://www.finanzen.net/nachricht/AVANT_Reports_First_Quarter_2008_Financial_Results_728165AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today reported financial results for the first quarter ended March 31, 2008. AVANT reported a net loss of $22.1 million, or $2.19 per share, for the first quarter of 2008 compared to a ...http://www.finanzen.net/nachricht/AVANT_Reports_First_Quarter_2008_Financial_Results_728165AVANT Announces Temporary Postponement of Conference Callhttp://www.finanzen.net/nachricht/AVANT_Announces_Temporary_Postponement_of_Conference_Call_727321AVANT Immunotherapeutic (NASDAQ: AVAN) today announced that it has postponed its first-quarter 2008 financial results call due to a delay in filing its Form 10-Q for the period ended March 31, 2008. The delay is necessary for management ...http://www.finanzen.net/nachricht/AVANT_Announces_Temporary_Postponement_of_Conference_Call_727321AVANT to Report First Quarter 2008 Financial Results on May 19, 2008http://www.finanzen.net/nachricht/AVANT_to_Report_First_Quarter_2008_Financial_Results_on_May_19_2008_725509AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its first quarter 2008 financial results before U.S. financial markets open on Monday, May 19, 2008. AVANT executives will host a conference call and live audio webcast ...http://www.finanzen.net/nachricht/AVANT_to_Report_First_Quarter_2008_Financial_Results_on_May_19_2008_725509Dr. Una Ryan Departs AVANT Immunotherapeuticshttp://www.finanzen.net/nachricht/Dr_Una_Ryan_Departs_AVANT_Immunotherapeutics_725108AVANT Immunotherapeutics (NASDAQ: AVAN) today announced the departure of Una Ryan, Ph.D, President and CEO, effective immediately. Over the last fifteen years, Dr. Ryan was instrumental in the development and partnering of multiple ...http://www.finanzen.net/nachricht/Dr_Una_Ryan_Departs_AVANT_Immunotherapeutics_725108